Navigation Links
Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association

-- Median time to pain progression is 66.1 weeks for the satraplatin arm compared with 22.3 weeks for the placebo arm -- Hazard ratio of 0.64 (95% CI: 0.51-0.79, p<0.001), representing a 36% reduction in the relative risk of pain progression

MARTINSRIED/MUNICH, Germany, May 21, 2007 /PRNewswire-FirstCall/ -- PRINCETON, N.J., and BOULDER, Colo. -- GPC Biotech AG and Pharmion Corporation today announced the presentation of additional data from the double-blind, randomized satraplatin Phase 3 registrational trial, the SPARC trial (Satraplatin and Prednisone Against Refractory Cancer). The data are being presented today at the Annual Meeting of the American Urological Association (AUA) in Anaheim, California. The SPARC trial is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone-refractory prostate cancer (HRPC) whose prior chemotherapy has failed. An NDA for satraplatin is currently under priority review by the U.S. FDA.

"Patients with metastatic hormone-refractory prostate cancer frequently suffer from substantial pain associated with bone metastases. Thus, pain control for these patients constitutes a major challenge and is an important goal when caring for them," said Oliver Sartor, M.D., Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Associate Professor at Harvard Medical School, Boston, MA, and principal investigator of the SPARC trial, who is presenting the satraplatin data today. "In addition to the very encouraging results for progression-free survival demonstrating a 33% lower risk of progression compared to control, it is exciting to see that the SPARC trial results show that treatment with satraplatin also results in a statistically significant improvement in time to pain progression."

Data presented today showed that the median time to pain progression was 66.1 weeks for the satraplatin arm compared with 22.3 weeks for
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:5/16/2013)... 16, 2013  Nektar Therapeutics, (Nasdaq: NKTR ) ... , is scheduled to present at the upcoming 2013 ... at the Sheraton New York Hotel on Tuesday, May ... presentation will be accessible via a Webcast through a link ... Nektar website: http://www.nektar.com . This Webcast will be available ...
(Date:5/16/2013)... May 16, 2013  Alere Inc. (NYSE: ALR ... of their health at home through the merger of rapid ... $3.00 per share on its Series B Convertible Perpetual Preferred ... 2013 to holders of record of Series B stock at ... Such payment will cover the amount of all dividends accrued ...
(Date:5/16/2013)... JACKSONVILLE, Florida , May 16, 2013 ... private practice in the U.S. to access the widely-used ... just a PC and Internet connection to get started. ... pre-operative planning software for over 10 years, is dedicated ... to template with digital x-ray images, when printed film ...
Breaking Medicine Technology:Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City 2OrthoView Announces the U.S. Launch of a New, Subscription-based, Digital Planning and Templating Solution for Individual Orthopaedic Surgeons 2
... N.J., Oct. 14 PDR Network, already the ... Alerts to U.S. prescribers, announced that this month ... Risk Evaluation and Mitigation Strategies ("REMS") program alerts ... electronically to prescribers by PDR Network,s Health Care ...
... Janam Technologies LLC, a ... and communicate wirelessly, today announced a new mobile ... Series product line with antimicrobial versions of the XM66 ... XM60+AM provide the healthcare sector with rugged antimicrobial ...
Cached Medicine Technology:PDR Network Delivers Six Million Drug Alerts & REMS 2PDR Network Delivers Six Million Drug Alerts & REMS 3Janam Introduces Mobile Healthcare Product Line 2
(Date:5/19/2013)... Fat Burning Furnace developed by Rob Poulos is ... fat burning diet plans, training workouts, and ... package, people will receive the Fat Burning Furnace manual, ... Fat Burning Furnace manual includes fat loss knowledge, and ... In addition, this book covers step-by-step instructions, techniques and ...
(Date:5/19/2013)... 2013 Dr. Keith Chertok now provides gum ... unhealthy gums and increase the chance of a healthier smile. ... Attachment Procedure (LANAP) not only removes diseased gum tissue in ... jaw bone for dental implants. , LANAP uses ... It can also help stimulate the healthy tissue as well ...
(Date:5/19/2013)... Seattle, Wa (PRWEB) May 19, 2013 Agora ... training program that covers guides on how to increase ... an innovative memory training method that helps people re-new their ... fight stress and beat depression caused by a fatigued mind. ... their mind razor sharp for a lifetime. The author claimed ...
(Date:5/19/2013)... Buenos Aires, Argentina: Yoga classes ( clases ... Aires, Argentina by the Sivananda Yoga Vedanta Center. ... - (Barrio Norte). Classes are 90 minutes and are ... offered in a calm environment, allowing visitors to enjoy ... vegetarian food, among others. , The Yoga classes follow ...
(Date:5/19/2013)... May 19, 2013 The legal team ... YazSideEffects.com in a concerted effort to connect women and ... birth control drugs Yaz, Yasmin & Ocella with the ... of information on the notorious birth control drugs as ... Pharmaceuticals. , Yaz, Yasmin & Ocella were very ...
Breaking Medicine News(10 mins):Health News:Fat Burning Diet | How “Fat Burning Furnace” Helps People Lose Their Weight Naturally And Fast – V-kool 2Health News:Berkeley, CA Periodontist, Dr. Keith Chertok Now Treats Gum Disease Patients With Laser Gum Surgery Prior to Placing Dental Implants 2Health News:How To Increase Memory Power | How “Agora Health Limited” Helps People Improve Their Memory Naturally And Effectively – Health Review 2Health News:Clases de Yoga in Buenos Aires, Argentina (Yoga Classes) Now Offered by Sivananda Yoga Vedanta Center 2Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2
... cells (progenitor cells) to treat the damage to cardiac ... Emory University School of Medicine. , The study investigators--Emory ... update their colleagues on its progress at the American ... "This is one of the first trials where patients ...
... Panomics Inc., a,developer of innovative technologies and ... exclusive provider of QuantiGene(R) and,QuantiGene Plex(R) products ... that they have been awarded Frost & ... Company of the Year,Award. Frost & Sullivan, ...
... Home Front Needs of Families with Deployed Service Members ... ... Alliance will,present $20,000 to the Utah National Guard Charitable Trust, to help,support the ... representatives Alice Demarais, market vice president for the,mountain region, and Tom Eurek, service ...
... flexibility and if employees perceive that flexibility as real, ... those employees, according to new research by lead author ... of Medicine., The study, titled The Effects of Workplace ... is published in the Dec. 11 issue of The ...
... 10 Novo Nordisk Inc.,today announced the company has ... infringed patents owned by Novo Nordisk.,The patents cover inhaled ... filed in August 2006 in United States,Federal Court in ... is a healthcare company with an 84-year history of,innovation ...
... presented today at the,American Society of Hematology (ASH) ... use of erythropoiesis-stimulating agents (ESAs),for chemotherapy-induced anemia (CIA) ... blood supply. Using a modeling simulation,technique that allowed ... use,findings suggested that even at the lowest reduction ...
Cached Medicine News:Health News:Adult stem cell heart attack study updated at American Society for Hematology Meeting 2Health News:Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award 2Health News:Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award 3Health News:TriWest Contributes $20,000 to Utah National Guard 2Health News:Employees with workplace flexibility have healthier lifestyle habits 2Health News:Modeling Simulation Predicts Potential Negative Impact on U.S. Blood Supply if ESA Use Limited for Chemotherapy-Induced Anemia 2Health News:Modeling Simulation Predicts Potential Negative Impact on U.S. Blood Supply if ESA Use Limited for Chemotherapy-Induced Anemia 3Health News:Modeling Simulation Predicts Potential Negative Impact on U.S. Blood Supply if ESA Use Limited for Chemotherapy-Induced Anemia 4Health News:Modeling Simulation Predicts Potential Negative Impact on U.S. Blood Supply if ESA Use Limited for Chemotherapy-Induced Anemia 5Health News:Modeling Simulation Predicts Potential Negative Impact on U.S. Blood Supply if ESA Use Limited for Chemotherapy-Induced Anemia 6
... provides the highest level of protection ... lead protective eyewear. Consistent lens ... allowed. Mfg supervised by Licensed and ... meet or exceed standards for optical ...
... large designer goggle includes a ... providing a more comfortable, even ... The head strap design is ... The acrylic side shields provide ...
... The wrap frame is constructed of extremely ... minimizing potential breakage. The molded wrap ... full saddle bridge to distribute weight evenly ... vision with leaded glass side shields. ...
... protection Properly manufactured radiation protective eyewear ... Our high quality frames and materials offer ... weight. Our lenses are made of Schott ... industry standards. Most Pulse Glasses are offered ...
Medicine Products: